Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)

Inclusion Criteria: 1. Patients between 18-70 years old 2. Negative urine pregnancy test in females 3. History of elevated liver associated enzymes (ALT \> 40) 4. Liver biopsy within 1 year of screening in this study that shows histopathologic findings consistent with NASH Exclusion Criteria: 1. ALT greater than three times normal 2. NYHA class 3 or 4 heart failure 3. Any congestive heart failure patient on insulin 4. Patients on one of the 3 study drugs within the past 3 months prior to enrollment 5. Alcohol consumption \>20 gm/day in a female and \> 30 gm/day in a male 6. Evidence of co-existent chronic liver disease to include viral hepatitis, Wilson's disease, autoimmune hepatitis, hemochromatosis, primary biliary cirrhosis, or primary sclerosing cholangitis 7. Serum creatinine on initial screening of greater than 1.4 8. Known hypersensitivity to rosiglitazone, metformin, or losartan 9. Known history of diabetic ketoacidosis 10. Female that is breastfeeding 11. Insulin dependent diabetic